EUVIMEDEUVIMED entdecken
Crossref

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits

Rita Rubin

JAMA · 2024

DOI: 10.1001/jama.2024.16432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Rita Rubin. Beteiligte Einrichtung: Lead Senior Staff Writer, Medical News & Perspectives, JAMA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Antiviral Agents, Post-Acute COVID-19 Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 Drug TreatmentAntiviral AgentsPost-Acute COVID-19 SyndromeHumansDrug CombinationsLactamsLeucineNitrilesProlineRitonavirSeverity of Illness IndexHealth InequitiesDrug Prescriptions

Substanzen

nirmatrelvir and ritonavir drug combinationDrug CombinationsAntiviral AgentsLactamsLeucineNitrilesProlineRitonavir

Autor:innen und Institutionen

  • Lead Senior Staff Writer, Medical News & Perspectives, JAMA.

Zitieren

APA

Rubin, R. (2024). The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. JAMA. https://doi.org/10.1001/jama.2024.16432

Vancouver

Rubin R. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. JAMA. 2024. doi:10.1001/jama.2024.16432

BibTeX
@article{Rubin2024,
  author = {Rubin, Rita},
  title = {The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.16432}
}
Kostenlos starten →